TARRAGONA SPAIN
01st 05th MARCH 2020

Joan Bladé
Hospital Clinic, Barcelona, Spain

ISA INTERNATIONAL SOCIETY OF AMYLOIDOSIS

ISA INTERNATIONAL SYMPOSIUM ON AMYLOIDOSIS

www.isa2020.org
**SUNDAY 1ST MARCH**

15:30  
**Registration Palau de Congressos Tarragona**

17:45  
**Welcome reception**

**MONDAY 2ND MARCH**

08:00 - 08:15  
**Welcome. Opening Remarks**  
Joan Bladé, Barcelona, Spain

08:15 - 08:45  
**Opening Lecture: Amyloidosis: Classification and Epidemiology**  
Chair: Joan Bladé, Barcelona, Spain

08:45 - 10:15  
**PLENARY SESSION 1**

**Basic Science: Amyloid Fibril Formation, Deposition and Clearance**
- Amyloid fibril structures using cryo EM and ssNMR
- Drivers of amyloid organ tropism and deposition
- Proteomics the diagnosis of AL and ATTR amyloidosis
- Proteotoxicity and organ damage
- Intrinsec mechanisms of amyloid tissue clearance
- Development of amyloid disruptors for ATTR amyloidosis

10:15 - 10:45  
**Coffee break**

10:45 - 12:00  
**PLENARY SESSION 2**

**AL amyloidosis: Diagnosis and Management in 2020**
- Diagnosis work-up and typing
- Red-flags for early diagnosis
- New prognostic markers
- Cytogenetics in AL amyloidosis
- Hematologic and organ response criteria

12:00 - 13:00  
**Opening ceremony and Giampaolo Merlini Award and Lecture**

13:00 - 14:30  
**Lunch and poster viewing**

**Nomenclature Committee Meeting**
14:30 - 16:00
**INDUSTRY SPONSORED SYMPOSIUM 1**

**Recognizing and Treating Cardiac Amyloidosis**
- Mechanisms and pattern of cardiac deposition in amyloidosis
- Recognition and diagnosis of ATTR cardiomyopathy
- Treatment of ATTR cardiomyopathy

16:00 - 17:00
**Selected Abstract presentations I**

17:00 - 17:30
Coffee break

17:30 - 18:30
**PLENARY SESSION 3**

**ATTR amyloidosis: Genetics and Basic Science**
- Molecular mechanisms of ATTR amyloidosis
- Genetic signatures associated with hereditary ATTR amyloidosis
- Factors involved in increased susceptibility to TTR amyloidogenesis
- Transition of wild-type ATTR amyloidosis

18:30 - 19:10
**Selected Abstract presentations II**

19:15 - 19:45
ISA Members Meeting

**TUESDAY 3RD MARCH**

07:00 - 08:00
**MEET-THE-EXPERT SESSIONS**
- Management of patients with ATTR polynuropathy
- Management of patients with ATTR cardiomyopathy
- Treatment of high-risk unfit patients with AL amyloidosis
- Treatment of fit patients with AL amyloidosis including ASCT
- Management of relapsed AL amyloidosis

08:00 - 09:00
**PLENARY SESSION 4**

**Organ Transplantation in Systemic Amyloidosis**
- Heart transplantation in AL amyloidosis
- Heart transplantation in ATTR amyloidosis
- Liver transplantation in hereditary ATTR amyloidosis
- Kidney transplant in AL amyloidosis and monoclonal immunoglobulin deposition disease: who and when?

09:00 - 10:30
**Selected Abstract presentations III**

10:30 - 11:00
Coffee break
11:00 - 12:30
**INDUSTRY SPONSORED SYMPOSIUM 2**

**Multidisciplinary Treatment Approach in the Management of Patients with AL Amyloidosis**
- Diagnostic pit-falls and risk stratification in AL amyloidosis (20 min + 10 min Q&A)
- Monoclonal antibody treatment for AL amyloidosis (20 min + 10 min Q&A)
- Novel targets and drugs for AL amyloidosis (20 min + 10 min Q&A)

12:30 - 14:00
**Lunch and poster viewing**
International Kidney MG working Group

14:00 - 15:15
**PLENARY SESSION 5**

**Autologous Stem-Cell Transplant in AL Amyloidosis:**
Overview (14:00-14:20)
Question and Answer Panel (14:20-15:00)

**Panelists:**
- Patient selection
- Decreasing transplant-related mortality
- Pretransplant induction
- ASCT in patients with renal function impairment
- Any role for consolidation or maintenance?
- Is it time for CAR-T cell therapy in AL amyloidosis?

15:15 - 15:45
**Coffee break**

15:45 - 17:15
**INDUSTRY SPONSORED SYMPOSIUM 3**

**Hereditary Transthyretin Amyloidosis**
- Multidisciplinary management and quality of life of patients with ATTR polyneuropathy
- Potential predictors of response and progression to treatment of hereditary TTR amyloidosis
- Treatment of hereditary TTR amyloidosis with antisense agents

17:15 - 18:05
**Selected Abstract presentations IV**
WEDNESDAY 4TH MARCH

07:00 - 08:00  MEET-THE-EXPERT SESSIONS
- Novel drugs for ATTR amyloidosis
- Organ transplant in systemic amyloidosis
- Practical approach to mutant TTR carriers
- Prevention and management of drug-related toxicities in systemic amyloidosis
- Imaging techniques in amyloidosis

08:00 - 09:15  PLENARY SESSION 6
Treatment of Patients with AL Amyloidosis non-eligible for ASCT with emphasis on Novel Agents
Overview (8:00-8:20)
Question and Answer Panel (8:20-9:15)
Panelists:
- Best initial therapy for fit patients
- Best initial therapy for unfit patients
- When to start therapy at relapse or progression
- Treatment at first relapse
- Treatment at later relapses or refractory disease
- Best novel emerging agents

09:15 - 10:35  Selected Abstract presentations V

10:35 - 11:00  Coffee break

11:00 - 12:30  INDUSTRY SPONSORED SYMPOSIUM 4
Hereditary Transthyretin Amyloidosis
- Mechanisms of organ damage in ATTR amyloidosis
- RNA interference for gene expression control in ATTR amyloidosis
- Hereditary ATTR amyloidosis: role of RNA interference therapy

12:30 - 14:00  Lunch and poster viewing
Taylor&Francis (managing editor of Amyloid)
PLENARY SESSION 7

Hereditary ATTR Amyloidosis: Clinical Features and Follow-up
- Clinical features of polyneuropathy in hereditary amyloidosis
- Red-flags for early diagnosis in hereditary amyloidosis
- The global prevalence of ATTR amyloidosis
- Unusual manifestations in ATTR amyloidosis
- Follow-up, polyneuropathy detection, de novo manifestations and treatment after domino liver transplantation

PLENARY SESSION 8

Other Forms of Amyloidosis
- Localized amyloidosis
- AA amyloidosis associated with autoinflammatory diseases
- Systemic wild-type ATTR amyloidosis
- Hereditary non-transthyretin amyloidosis
- CNS and ocular involvement in hereditary amyloidosis
- LECT2-associated renal amyloidosis
THURSDAY 5TH MARCH

08:00 - 09:00  
Selected Abstract presentations VI

09:00 - 10:15  
HOT TOPICS IN SYSTEMIC AMYLOIDOSIS

Question and Answer Panel
- Are we curing AL amyloidosis in 2020?
- Is there a role for MRD assessment?
- When to suspect AL amyloidosis during MGUS follow-up?
- What is the real prevalence of wild type ATTR amyloidosis?
- Amyloid deposition in organ transplant recipients
- Best treatment approach at lack of response to patisiran or inotersen in ATTR
- Is it time for combination therapy trials in ATTR?
- Is there a role for anti-amyloid therapy? (anti-SAP, doxycycline, others)

10:15 - 10:45  
Coffee break

10:45 - 11:45  
PLENARY SESSION 9

Clinical Trials in Progress in Systemic Amyloidosis

11:45 - 12:00  
Symposium Overview and Future Prospects

12:00 - 12:30  
The next symposium

12:30 - 13:30  
Lunch and departures